Expert Perspectives on Biosimilar Agents

In this video module, a multidisciplinary panel of expert faculty discuss the use of biosimilars across oncology, rheumatology, dermatology, and gastroenterology specialties.

This program is divided into four segments. After clicking the Launch buttons below, the player will open in a new window. If it doesn’t appear, please disable your pop-up blocker and try again. After reviewing all segments, click the Claim Credit button to the right to complete the CME posttest and evaluation.

Andrew M. Evens, DO, MSc, FACP Jonathan Kay, MD Alan C. Moss, MD Physicians: maximum of 1.5 AMA PRA Category 1 Credits™ Released: November 16, 2017 Expiration: November 15, 2018

Part 1: Fundamentals (48 minutes)

Part 2: Inflammatory Diseases (12 minutes)

Part 3: Oncology (11 minutes)

Part 4: Challenges (5 minutes)

In these downloadable slides, a multidisciplinary panel of expert faculty discuss the use of biosimilars across oncology, rheumatology, dermatology, and gastroenterology specialties.

As biosimilars penetrate the GI treatment space, here’s my take on what gastroenterologists need to know.

Russell D. Cohen, MD, FACG, AGAF Released: December 6, 2017

Despite demonstration of comparable efficacy and safety between biosimilars and their originators, some patients avoid this treatment switch. Here’s my take on steps to assuage unfounded patient fears.

Jonathan Kay, MD Released: February 13, 2018